Normal view MARC view ISBD view

Overdose : how excessive government regulation stifles pharmaceutical innovation / Richard A. Epstein.

by Epstein, Richard Allen; Yale University. Institute for Policy Innovation.
Material type: materialTypeLabelBookPublisher: New Haven, Conn. : Yale University Press, c2006Description: xi, 283 p. ; 25 cm.ISBN: 9780300143263.Subject(s): United States. Food and Drug Administration | United States. Food and Drug Administration | Pharmaceutical industry -- Government policy -- United States | Drug Industry -- United States | Government Regulation -- United States | Public Policy -- United StatesDDC classification: 338.4 E64 Online resources: Contributor biographical information | Publisher description | Table of contents only
Contents:
Rising expectations-- and diminishing returns -- Property generally : externalities, coordination, and the public domain -- Intellectual property: the public domain and private rights -- Taming conflict of interests -- Federally sponsored research under Bayh-Dole -- The anticommons -- The single monopoly : current patent limitations -- Rate regulation : an unneeded swamp -- Patent purchases: a second swamp -- Socialization of R & D : the final swamp -- The steady expansion of FDA power -- FDA versus the individual : upstream or downstream decision making -- Drug withdrawal : too much, too soon -- Getting the drugs to market -- Deceptive marketing -- Tort preliminaries -- Product liability for prescription drugs : manufacturing and design cases -- The main event : misrepresentation, overpromotion, and duty to warn -- Conclusion : socialized medicines.

"An Institute for Policy Innovation Book."

June 2009 Selected Accessions List.

Includes bibliographical references (p. 241-271) and index.

Rising expectations-- and diminishing returns -- Property generally : externalities, coordination, and the public domain -- Intellectual property: the public domain and private rights -- Taming conflict of interests -- Federally sponsored research under Bayh-Dole -- The anticommons -- The single monopoly : current patent limitations -- Rate regulation : an unneeded swamp -- Patent purchases: a second swamp -- Socialization of R & D : the final swamp -- The steady expansion of FDA power -- FDA versus the individual : upstream or downstream decision making -- Drug withdrawal : too much, too soon -- Getting the drugs to market -- Deceptive marketing -- Tort preliminaries -- Product liability for prescription drugs : manufacturing and design cases -- The main event : misrepresentation, overpromotion, and duty to warn -- Conclusion : socialized medicines.

Powered by Koha